A new study protocol published in Trials outlines the framework for the Accelerated translational research in PRImary liver CAncer (APRICA) trial, a randomized controlled trial designed to assess the impact of integrating palliative care into routine hepatocellular carcinoma (HCC) ambulatory clinics. The study, led by researchers at multiple institutions across Australia, addresses the critical need for improved supportive care for patients with HCC.
HCC poses a significant global health burden, and while advancements in treatment have improved survival, many patients experience substantial symptom burden and reduced quality of life. Current models of care often fail to adequately address these supportive care needs, highlighting the importance of early palliative care intervention.
The APRICA trial aims to bridge this gap by evaluating the feasibility and effectiveness of integrating palliative care into the standard oncology setting. The trial will randomize patients with HCC receiving treatment at participating ambulatory clinics to either integrated palliative care or standard oncology care alone. The integrated palliative care intervention will involve a multidisciplinary team providing comprehensive symptom management, psychosocial support, and advance care planning.
The primary outcome of the trial is to assess the impact of integrated palliative care on patient-reported quality of life, measured using validated instruments. Secondary outcomes include assessments of symptom burden, healthcare utilization, and patient satisfaction. The study will also evaluate the impact of the intervention on caregiver burden and satisfaction.
"This trial represents a crucial step towards improving the holistic care of patients with HCC," said Dr. Cait Gofton, lead author of the study protocol. "By integrating palliative care early in the disease trajectory, we hope to alleviate suffering and improve the overall well-being of patients and their families."
The study protocol provides a detailed description of the trial design, including eligibility criteria, randomization procedures, intervention components, and data collection methods. The researchers emphasize the importance of rigorous methodology to ensure the validity and generalizability of the findings. The results of the APRICA trial are expected to provide valuable insights into the optimal approach to integrating palliative care into routine oncology practice for patients with HCC.
